Evidence map›Paper›PMID 40779629›Full record

ArticleScience advances2025

HLF transactivates

Daimin Xiang, Zhao Yang, Mingye Gu, Midie Xu, Chunliang Liu, Erdong Liu, Junyu Liu, Yichuang Wang, Hongyang Wang, Jing Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daimin XiangInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.ORCID 0000-0002-1386-8082
Zhao YangDepartment of Hepatobiliary Surgery, Third Affiliated Hospital of Naval Military Medical University, Shanghai 200438, China.ORCID 0000-0003-4668-6127
Mingye GuInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.ORCID 0009-0004-1082-2881
Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0003-1775-6608
Chunliang LiuInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.
Erdong LiuInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.ORCID 0009-0007-7084-999X
Junyu LiuInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.
Yichuang WangInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.
Hongyang WangInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.ORCID 0000-0002-4709-3334
Jing FuInternational Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.ORCID 0009-0002-6769-525X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is the most common malignancy in the biliary system and lacks biomarkers for personalized therapy. Here, we reported that hepatic leukemia factor (HLF) was highly expressed in gallbladder cancer stem cells (CSCs) and patients with gemcitabine-resistant GBC. Mechanistic study revealed that interleukin-6 receptor (IL-6R) and transcription factor EB (TFEB) are direct target genes of HLF. The IL-6/IL-6R/signal transducer and activator of transcription 3 axis transactivates HLF expression in GBC, forming a positive feedback loop. Functional studies revealed that HLF promoted gallbladder CSCs' expansion and gemcitabine resistance via TFEB-induced autophagy. In addition, HLF drives TFEB-induced programmed death ligand 1 expression in human tumors and governs tumor immune evasion in a CD8

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell Self RenewalGallbladder NeoplasmsNeoplastic Stem CellsAnimalsCell Line, TumorCell ProliferationDeoxycytidineDrug Resistance, NeoplasmGemcitabineGene Expression Regulation, NeoplasticHumansInterleukin-6MiceReceptors, Interleukin-6Signal TransductionBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsDeoxycytidineGemcitabineInterleukin-6Receptors, Interleukin-6TFEB protein, human

Identifiers

PMID40779629
PMCPMC12333681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.